Eckert & Ziegler Awards Travel Grants to Young Scientists in Nuclear Medicine
The goal of the Eckert & Ziegler/EANM abstract award is to strengthen the collaboration between researchers and clinicians to expedite the implementation of research findings for the benefit of the patient. We hope that this will help to ensure that the substantial progress which has been made in medical imaging can soon be transformed into more precise, faster or less expensive methods of diagnosis and therapy.
"Due to current demographic trends, we have seen a significant increase in neurodegenerative diseases, such as Alzheimer's and Parkinson's. With the Positron Emissions Tomography (PET), such diseases can be detected at an early stage and treated. Moreover, the trend of personalized medicine is being supported by nuclear medical imaging. For example, PET scans can detect the properties of a tumor, which can determine the basis for the individualized treatment of a patient," commented Dr. André Heß, Member of the Board at Eckert & Ziegler AG and Head of the Segment Radiopharma.
Eligibility for Participation:
All EANM members who are not older than 38 years of age at the time of submission are eligible to participate. Applications can be submitted electronically via http://eanm12.eanm.org. The submission deadline is 16 April 2012.
Eckert & Ziegler Strahlen- und Medizintechnik AG
The Eckert & Ziegler Group, with more than 580 employees, is one of the world's largest providers of isotope component technology for radiation therapy and nuclear medicine. Eckert & Ziegler supports the wide-spread use of PET/CT hybrid systems by expanding its production sites for radioactive contrast agents and by developing automated synthesis modules in which scientists can produce new diagnostic substances with the requisite pharmaceutical quality.